Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Precision medicine

Increase throughput. Eliminate contaminants and immunogenicity.

Precision medicine

Neoantigens, or tumor mutated specific antigens, are major tumor rejection antigens, allowing tumors to activate the immune system and induce an efficient anti-tumor response. As personalized medicine for cancer therapeutics ramps up and becomes more feasible and affordable, individual patient neoantigen development is increasingly important. Identification of these neoantigens has greatly improved, with recent advancements in deep sequencing and bioinformatics technologies. Gene synthesis and mRNA production then allow for these predicted neoantigens to be synthesized and tested for T cell reactivity, differentiating true immunogenic neoepitopes from putative ones. Since patients’ mutated antigens are largely unique to the individual, speed is one of the most important goals in identifying and verifying true neoantigens for induction of the T cell-mediated immune response.

Precision medicine

Accelerating personalized neoantigen synthesis

The BioXp™ system’s on-demand, high-throughput gene and mRNA* synthesis and flexible cloning into a variety of vectors allow for quick screening and development of personalized cancer treatments. Gibson Assembly® RapidAMP™ cloning and amplification process avoids the use of E. coli, thus eliminating endotoxin contamination and unwanted immunogenicity.

Learn more

*Not yet available for sale. No guarantee of release is implied.

Contact us

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.